Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

llion (2006: US$nil) of which US$205.0 million (2006: US$nil) relates to capitalised in-process R&D ("IPR&D") for DYNEPO (primarily the oncology indication), as the Group considers it unlikely that it will pursue the indication for commercialisation. See Note 7 for further details.

Excluding these intangible impairment charges of US$256.4 million and the US$100.0 million charge on the effective settlement of the pre-existing relationship with New River, R&D expenditure in the year to December 31, 2007 was US$418.8 million or 19% of product sales (2006: US$295.8 million) an increase of US$123.0 million.

The increase in R&D expenditure in 2007 was due to Phase 3(b) and Phase 4 studies to support new product launches; the continuation of Phase 3 trials on velaglucerase alfa (GA-GCB); the development of the Women's Health franchise and JUVISTA; the pre-clinical development of three HGT projects and the newly in-licensed products from Amicus Therapeutics, Inc. ("Amicus") and Alba Therapeutics Corporation ("Alba").

For the year to December 31, 2007 R&D included a charge of US$16.6 million (2006: US$3.9 million) for share based compensation which included a US$4.6 million (2006: US$nil) cumulative catch up charge in respect of 2005 option awards, for further information see SG&A below.

Selling, general and administrative (SG&A) expenses

SG&A expenses increased from US$1,219.9 million (79% of product sales) in the year to December 31, 2006 to US$1,381.1 million in 2007 (64% of product sales), an increase of 13%, which is less than the product sales increase of 41%.

Year to December 31, 2007 2006 Change

US$M US$M %

_______ _______ _______

Sales costs 310.7 233.2 +33

Marketing costs 401
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... SureClinical, a leader in cloud-based health ... joined SureClinical’s executive team as Chief Financial Officer. ... executive with over 25 years in leadership roles ranging ... Ms. Morris joins SureClinical from Marrone Bio Innovations (MBI), ... of MBI from its founding in 2006 until 2011, ...
(Date:4/29/2015)... 2015 According to a new ... Product (Portable & Non-Portable), Component (Accelerometer, Proximity Probe, ... Metal & Mining, & Others), & Geography - ... expected to reach $1,453.76 Million by 2020, at ... data tables and 92 figures spread through 205 ...
(Date:4/29/2015)... , April 29, 2015   Doximity , the ... all US doctors as members, announced a new, instant ... "Apply Using Doximity." With one click, all US physicians ... curriculum vitae (CV) for an open job opportunity, and ... Eighty seven percent of physicians are open ...
(Date:4/29/2015)... Poway, CA (PRWEB) April 29, 2015 ... proud to announce that its regenerative stem cell therapy ... founded in 2002, seeking to discover a successful treatment ... ligaments. , In 2003 VetStem signed a worldwide exclusive ... veterinary application, and the first horse was treated in ...
Breaking Biology Technology:Julie I. Morris Joins SureClinical as Chief Financial Officer 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4Doximity Offering Hospitals Easy, Efficient Physician Application Tool 2VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2
... 27 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... a live webcast and conference call of presentations made ... Society of Clinical Oncology Annual Meeting (ASCO) on Saturday, ... p.m. EDT. , During the reception, OncoGenex management and ...
... including the mentally ill, the disabled and ethnic minorities ... than others in the aftermath of natural disasters, suffering ... Now, a new study by UCLA researchers and colleagues ... and make more behavioral changes based on those fears ...
... the origin and time of an aerosolized release of ... few cases has been developed by researchers from the ... Modelling at Imperial College London in collaboration with the ... The method, described in an article published April 10 ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009 2Disabled and other vulnerable groups more susceptible to terrorism fears 2Novel method predicts impact of a covert anthrax release 2
(Date:4/21/2015)... High crime rate, increasing ... access control systems market in Saudi Arabia ... published report by TechSci Research " Saudi Arabia Access Control ... systems market in Saudi Arabia ... control systems market in the Kingdom is growing at ...
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2
... are an invaluable part of the marine ecosystem, fostering ... Pathogenic bacteria, along with pollution and harmful fishing practices, ... coral populations today. One of the solutions ... Eugene Rosenberg of Tel Aviv University,s Department of Molecular ...
... but they are also necessary. Researchers at the University ... invention that makes clinical trials more efficient by moving ... Bank," the computer software eye modeling program includes data ... their inventions. Developed by Ying-Ling Chen, research assistant professor ...
... who are highly exposed to common environmental chemicals - ... at birth and larger at 20 months of age, ... of Public Health published online in the August 30 ... are used in the production of fluoropolymers and are ...
Cached Biology News:Viruses could be the key to healthy corals 2University of Tennessee Space Institute researchers make clinical trials a virtual reality 2Chemical exposure in the womb from household items may contribute to obesity 2
Agar, 500 g. Noble Agar.Moisture: < 10%, ash: < 1.6%, EEO (-mr): < 0.450 (pH 8.4). Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
MW5...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Biology Products: